Amicogen Inc
KOSDAQ:092040
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Amicogen Inc
Total Current Liabilities
Amicogen Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Amicogen Inc
KOSDAQ:092040
|
Total Current Liabilities
₩80.7B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
3%
|
CAGR 10-Years
6%
|
|
|
Celltrion Inc
KRX:068270
|
Total Current Liabilities
₩4.5T
|
CAGR 3-Years
51%
|
CAGR 5-Years
33%
|
CAGR 10-Years
21%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Total Current Liabilities
₩21.3B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Total Current Liabilities
₩6.8B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Current Liabilities
₩239.7B
|
CAGR 3-Years
36%
|
CAGR 5-Years
62%
|
CAGR 10-Years
89%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Total Current Liabilities
₩123.5B
|
CAGR 3-Years
20%
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
|
Amicogen Inc
Glance View
Amicogen, Inc. engages in the development and sale of enzyme products and functional food materials. The company is headquartered in Jinju, Gyeongsangnam-Do. The company went IPO on 2013-09-12. The Company’s products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The firm distributes its products within domestic market and to overseas markets, including China, Japan, the United Sates, Germany and Thailand.
See Also
What is Amicogen Inc's Total Current Liabilities?
Total Current Liabilities
80.7B
KRW
Based on the financial report for Dec 31, 2025, Amicogen Inc's Total Current Liabilities amounts to 80.7B KRW.
What is Amicogen Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
6%
Over the last year, the Total Current Liabilities growth was -19%. The average annual Total Current Liabilities growth rates for Amicogen Inc have been -27% over the past three years , 3% over the past five years , and 6% over the past ten years .
